Annotation Detail for SLITRK5
Basic Information
Top
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| D003561 |
Cytarabine |
Cytarabine results in decreased expression of SLITRK5 mRNA | decreases expression | 19194470
|
| D014635 |
Valproic Acid |
Valproic Acid results in increased expression of SLITRK5 mRNA | increases expression | 19101580
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D000014 |
Abnormalities, Drug-Induced |
|
Valproic Acid |
4.37 | 8875741 |
| MESH:D000015 |
Abnormalities, Multiple |
|
Valproic Acid |
4.48 | 19490988 |
| MESH:D000550 |
Amblyopia |
|
Valproic Acid |
6.30 | 17688650 |
| MESH:D001008 |
Anxiety Disorders |
|
Valproic Acid |
3.98 | 17497229 |
| MESH:D001321 |
Autistic Disorder |
|
Valproic Acid |
1.98 | 19460635 18177632 20603192 17688650 18985861 18316065 15238991 18775368 19232924 16609825 18558336 17507914 18396377 17157402 18940202 |
| MESH:D001714 |
Bipolar Disorder |
|
Valproic Acid |
3.28 | 17594078 20046352 |
| MESH:D001848 |
Bone Diseases, Developmental |
|
Valproic Acid |
3.69 | 8888407 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cytarabine |
4.58 | 8243401 |
| MESH:D002659 |
Child Development Disorders, Pervasive |
|
Valproic Acid |
2.84 | 20734317 |
| MESH:D019465 |
Craniofacial Abnormalities |
|
Valproic Acid |
1.91 | 8888407 16575769 17688650 |
| MESH:D056486 |
Drug-Induced Liver Injury |
|
Valproic Acid |
2.27 | 1733752 19641884 |
| MESH:D004421 |
Dystonia |
|
Valproic Acid |
4.66 | 1851702 |
| MESH:D004831 |
Epilepsies, Myoclonic |
|
Valproic Acid |
4.92 | 17275665 3659116 |
| MESH:D004828 |
Epilepsies, Partial |
|
Valproic Acid |
4.98 | 3922381 16628512 |
| MESH:D004827 |
Epilepsy |
|
Valproic Acid |
3.14 | 18234410 20417680 |
| MESH:D004832 |
Epilepsy, Absence |
|
Valproic Acid |
4.06 | 7562514 6254150 6426943 |
| MESH:D017029 |
Epilepsy, Complex Partial |
|
Valproic Acid |
5.06 | 7750514 |
| MESH:D004830 |
Epilepsy, Tonic-Clonic |
|
Valproic Acid |
4.95 | 3659116 |
| MESH:D005234 |
Fatty Liver |
|
Valproic Acid |
3.85 | 19224547 14986274 |
| MESH:D005315 |
Fetal Diseases |
|
Valproic Acid |
5.96 | 16575769 |
| MESH:D005317 |
Fetal Growth Retardation |
|
Valproic Acid |
4.81 | 8888407 18558336 |
| MESH:D006689 |
Hodgkin Disease |
|
Cytarabine |
4.89 | 16200630 |
| MESH:D006849 |
Hydrocephalus |
|
Valproic Acid |
5.75 | 17688650 |
| MESH:D015470 |
Leukemia, Myeloid, Acute |
|
Valproic Acid |
2.21 | 17596541 16294345 |
| MESH:D017563 |
Lung Diseases, Interstitial |
|
Valproic Acid |
5.33 | 17228818 |
| MESH:D008881 |
Migraine Disorders |
|
Valproic Acid |
3.53 | 18803445 18765137 |
| MESH:D009139 |
Musculoskeletal Abnormalities |
|
Valproic Acid |
4.58 | 8888407 |
| MESH:D009190 |
Myelodysplastic Syndromes |
|
Valproic Acid |
3.40 | 17596541 |
| MESH:D009436 |
Neural Tube Defects |
|
Valproic Acid |
3.42 | 8888407 16359493 |
| MESH:D009771 |
Obsessive-Compulsive Disorder |
marker/mechanism |
|
| 20418887 |
| MESH:D054198 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
|
Cytarabine |
4.67 | 21297632 |
| MESH:D011297 |
Prenatal Exposure Delayed Effects |
|
Valproic Acid |
4.71 | 20603192 |
| MESH:D019310 |
Pseudolymphoma |
|
Valproic Acid |
5.61 | 12752131 11422049 |
| MESH:D012208 |
Rhabdomyosarcoma |
|
Valproic Acid |
4.78 | 19155313 |
| MESH:D012559 |
Schizophrenia |
|
Valproic Acid |
2.11 | 15737665 19110320 |
| MESH:D012640 |
Seizures |
|
Valproic Acid |
3.05 | 11044598 16876388 3137016 17978042 14763951 15475178 1511512 11738929 |
| MESH:D016135 |
Spinal Dysraphism |
|
Valproic Acid |
4.17 | 19490988 |
| MESH:D013226 |
Status Epilepticus |
|
Valproic Acid |
5.61 | 12833885 |
| MESH:D014178 |
Translocation, Genetic |
|
Valproic Acid |
6.30 | 17262798 |
| MESH:D020194 |
Unverricht-Lundborg Syndrome |
|
Valproic Acid |
5.41 | 3119515 |
| MESH:D014564 |
Urogenital Abnormalities |
|
Valproic Acid |
5.41 | 8888407 |
Related Pathway Information